Understanding the Research Background

Oct 13, 2025 by talynt.org 1 views

Analysis of the Effectiveness of Antibiotics Costs in Pneumonia Patient Therapy at H. Adam Malik Hospital

Pneumonia is a common disease that affects various age groups, and its treatment is a significant concern for healthcare providers. At H. Adam Malik Hospital, the use of antibiotics in pneumonia patients has been a topic of discussion due to the differences in costs and effectiveness. This study aims to analyze the effectiveness of the cost of antibiotics in patients with mild to moderate pneumonia at H. Adam Malik Hospital during 2018.

Understanding the Research Background

The use of antibiotics in pneumonia patients is a crucial aspect of treatment, but it can also be a significant cost factor. The variation in antibiotic therapy models is a key factor that contributes to the differences in costs and effectiveness. In this study, we aim to evaluate the treatment method used to determine the most cost-effective therapy options for patients. By analyzing the use of antibiotics in pneumonia patients at H. Adam Malik Hospital, we can provide better insight into the most efficient antibiotics in terms of costs and effectiveness.

Research Purposes and Objectives

The main objective of this study is to analyze the effectiveness of the cost of the use of antibiotics in patients who experience mild to moderate pneumonia at H. Adam Malik Hospital during 2018. With the right analysis, it is expected to obtain information about the most efficient antibiotics in terms of costs and effectiveness. This study aims to provide a comprehensive understanding of the cost-effectiveness of antibiotics in pneumonia patients, which can help healthcare providers make informed decisions about treatment options.

Research Methods and Design

This study uses the cohort method with a retrospective approach. Data was collected from a medical record of 77 patients with mild and medium pneumonia. Patient characteristics and antibiotic therapy models are analyzed descriptively. Furthermore, the cost and effectiveness of antibiotics are evaluated through cost-effectiveness (CEA) analysis, calculating the cost-effectiveness ratio (Cerior) and incremental cost-effectiveness ratio (ICER). Sensitivity analysis is also carried out to measure the effect of changes in drug costs on the results of the study, with variations in an increase in cost of 2.5%, 5%, and 7.5%.

Research Results and Findings

The results showed that pneumonia was more common in men (55.84%) with an average age of patients around 48 years. Analysis of cost effectiveness reveals that sephriaksone antibiotics are the most cost-effective choice for mild and moderate pneumonia patients, with a short story of Rp 70,881 for mild pneumonia and Rp 98,883 for moderate pneumonia. Interestingly, sensitivity analysis shows that the cost changes up to 7.5% do not change the status of sephriaxone as the most cost-effective antibiotics.

Conclusion and Implications

Based on the results of the study, it can be concluded that sephriakson is the most cost-effective antibiotics for patients with mild and moderate pneumonia at H. Adam Malik Hospital. These results provide a strong foundation for considering sephriakson as an antibiotic therapy standard for pneumonia patients in the hospital. This information is important for better decision making in the management of pneumonia patients, not only in terms of the effectiveness of treatment but also in terms of costs incurred. This research is expected to help other hospitals in determining better therapeutic choices in an effort to improve the quality of health services.

Limitations and Future Directions

This study has several limitations, including the small sample size and the retrospective design. Future studies should aim to replicate this study with a larger sample size and a prospective design. Additionally, further research is needed to explore the long-term effects of sephriakson on pneumonia patients and to compare its effectiveness with other antibiotics.

Recommendations for Practice

Based on the findings of this study, we recommend that healthcare providers consider sephriakson as a first-line treatment option for patients with mild and moderate pneumonia. This recommendation is based on the cost-effectiveness analysis, which shows that sephriakson is the most cost-effective choice for these patients. Additionally, healthcare providers should consider the results of this study when making decisions about antibiotic therapy for pneumonia patients.

Conclusion

In conclusion, this study provides valuable insights into the cost-effectiveness of antibiotics in pneumonia patients at H. Adam Malik Hospital. The results show that sephriakson is the most cost-effective antibiotics for patients with mild and moderate pneumonia. These findings have important implications for healthcare providers and policymakers, who can use this information to make informed decisions about antibiotic therapy for pneumonia patients.
Q&A: Analysis of the Effectiveness of Antibiotics Costs in Pneumonia Patient Therapy at H. Adam Malik Hospital

In our previous article, we discussed the analysis of the effectiveness of antibiotics costs in pneumonia patient therapy at H. Adam Malik Hospital. In this article, we will answer some of the frequently asked questions related to this study.

Q: What is the main objective of this study?

A: The main objective of this study is to analyze the effectiveness of the cost of the use of antibiotics in patients who experience mild to moderate pneumonia at H. Adam Malik Hospital during 2018.

Q: What is the significance of this study?

A: This study is significant because it provides a comprehensive understanding of the cost-effectiveness of antibiotics in pneumonia patients. The results of this study can help healthcare providers make informed decisions about antibiotic therapy for pneumonia patients.

Q: What is the methodology used in this study?

A: This study uses the cohort method with a retrospective approach. Data was collected from a medical record of 77 patients with mild and medium pneumonia. Patient characteristics and antibiotic therapy models are analyzed descriptively. Furthermore, the cost and effectiveness of antibiotics are evaluated through cost-effectiveness (CEA) analysis, calculating the cost-effectiveness ratio (Cerior) and incremental cost-effectiveness ratio (ICER).

Q: What are the results of this study?

A: The results showed that pneumonia was more common in men (55.84%) with an average age of patients around 48 years. Analysis of cost effectiveness reveals that sephriaksone antibiotics are the most cost-effective choice for mild and moderate pneumonia patients, with a short story of Rp 70,881 for mild pneumonia and Rp 98,883 for moderate pneumonia.

Q: What are the implications of this study?

A: The implications of this study are that sephriakson is the most cost-effective antibiotics for patients with mild and moderate pneumonia at H. Adam Malik Hospital. These results provide a strong foundation for considering sephriakson as an antibiotic therapy standard for pneumonia patients in the hospital.

Q: What are the limitations of this study?

A: This study has several limitations, including the small sample size and the retrospective design. Future studies should aim to replicate this study with a larger sample size and a prospective design.

Q: What are the recommendations for practice based on this study?

A: Based on the findings of this study, we recommend that healthcare providers consider sephriakson as a first-line treatment option for patients with mild and moderate pneumonia. This recommendation is based on the cost-effectiveness analysis, which shows that sephriakson is the most cost-effective choice for these patients.

Q: What are the future directions for this study?

A: Future studies should aim to replicate this study with a larger sample size and a prospective design. Additionally, further research is needed to explore the long-term effects of sephriakson on pneumonia patients and to compare its effectiveness with other antibiotics.

Q: How can this study be applied in real-world settings?

A: The results of this study can be applied in real-world settings by healthcare providers who are making decisions about antibiotic therapy for pneumonia patients. The cost-effectiveness analysis can help healthcare providers choose the most cost-effective antibiotics for their patients.

Q: What are the potential benefits of this study?

A: The potential benefits of this study are that it can help healthcare providers make informed decisions about antibiotic therapy for pneumonia patients, which can lead to better patient outcomes and reduced healthcare costs.